Novonesis Posts 7% Organic Sales Growth in 2025, Eyes Margin Expansion in 2026
Event summary
- Novonesis reported 7% organic sales growth in 2025, with adjusted EBITDA margin at 37.1%.
- Food & Health segment grew 8%, while Planetary Health saw 6% growth, including double-digit gains in Energy.
- Emerging Markets expanded 9% organically, outpacing Developed Markets' 6% growth.
- Adjusted net profit rose 17%, with free cash flow before acquisitions at EUR 770.4 million (19% of sales).
- 2026 outlook targets 5-7% organic sales growth and adjusted EBITDA margin of 37-38%.
The big picture
Novonesis' strong 2025 performance underscores its strategic focus on biosolutions, with broad-based growth across segments. The company's ability to navigate currency headwinds and market exits highlights operational resilience. As it targets further margin expansion in 2026, investors will watch how it balances pricing strategies and sales synergies against potential consumer sentiment shifts.
What we're watching
- Market Segmentation
- How Novonesis sustains its outperformance in Emerging Markets amid potential consumer sentiment challenges.
- Margin Dynamics
- Whether the company can expand EBITDA margins despite currency headwinds and exit costs from certain countries.
- Innovation Impact
- The pace at which new product launches (33 in 2025) translate into sustained revenue growth.
Related topics